Deborah K. Armstrong
About
Deborah K. Armstrong is a scholar working on Reproductive Medicine, Oncology and Surgery.
According to data from OpenAlex, Deborah K. Armstrong has authored 206 papers receiving a total of 14.0k indexed citations (citations by other indexed papers that have themselves been cited), including 120 papers in Reproductive Medicine, 85 papers in Oncology and 63 papers in Surgery. Recurrent topics in Deborah K. Armstrong's work include Ovarian cancer diagnosis and treatment (120 papers), Intraperitoneal and Appendiceal Malignancies (57 papers) and Endometrial and Cervical Cancer Treatments (28 papers). Deborah K. Armstrong is often cited by papers focused on Ovarian cancer diagnosis and treatment (120 papers), Intraperitoneal and Appendiceal Malignancies (57 papers) and Endometrial and Cervical Cancer Treatments (28 papers). Deborah K. Armstrong collaborates with scholars based in United States, United Kingdom and Japan. Deborah K. Armstrong's co-authors include Robert E. Bristow, Rafael S. Tomacruz, F.J. Montz, Edward L. Trimble, Joan L. Walker, Danijela Jelovac, Helen Huang, Robert A. Burger, Lari Wenzel and Larry J. Copeland and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Oncology.
In The Last Decade
Deborah K. Armstrong
201 papers receiving 13.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Deborah K. Armstrong United States | 55 | 8.1k | 5.0k | 4.3k | 3.0k | 2.9k | 206 | 14.0k | ||
| Robert A. Burger United States | 48 | 9.1k 1.1× | 4.4k 0.9× | 4.6k 1.1× | 3.6k 1.2× | 3.7k 1.3× | 202 | 14.8k | ||
| Gabriella Ferrandina Italy | 63 | 5.7k 0.7× | 3.4k 0.7× | 4.8k 1.1× | 4.6k 1.5× | 4.6k 1.6× | 496 | 15.8k | ||
| Pierluigi Benedetti Panici Italy | 63 | 6.6k 0.8× | 3.9k 0.8× | 3.6k 0.8× | 2.8k 0.9× | 6.7k 2.3× | 566 | 16.0k | ||
| William A. Cliby United States | 64 | 6.8k 0.8× | 4.2k 0.8× | 3.5k 0.8× | 3.8k 1.3× | 5.2k 1.8× | 288 | 14.3k | ||
| Maurie Markman United States | 63 | 7.9k 1.0× | 6.6k 1.3× | 6.4k 1.5× | 4.3k 1.4× | 2.7k 1.0× | 417 | 19.9k | ||
| Jonathan S. Berek United States | 67 | 8.1k 1.0× | 4.7k 1.0× | 4.3k 1.0× | 1.9k 0.6× | 7.4k 2.6× | 297 | 16.6k | ||
| Thomas J. Herzog United States | 64 | 6.2k 0.8× | 3.3k 0.7× | 3.2k 0.7× | 1.8k 0.6× | 6.1k 2.1× | 334 | 13.3k | ||
| Gordon Rustin United Kingdom | 67 | 5.1k 0.6× | 3.4k 0.7× | 5.3k 1.2× | 4.0k 1.3× | 1.3k 0.4× | 245 | 16.0k | ||
| Jalid Sehouli Germany | 65 | 7.8k 1.0× | 4.3k 0.9× | 5.9k 1.4× | 5.8k 1.9× | 3.8k 1.3× | 866 | 19.2k | ||
| Ross S. Berkowitz United States | 66 | 5.4k 0.7× | 2.4k 0.5× | 2.7k 0.6× | 4.6k 1.5× | 2.9k 1.0× | 445 | 18.7k |
Countries citing papers authored by Deborah K. Armstrong
Since
Specialization
Citations
This map shows the geographic impact of Deborah K. Armstrong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah K. Armstrong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah K. Armstrong more than expected).
Fields of papers citing papers by Deborah K. Armstrong
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Deborah K. Armstrong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah K. Armstrong. The network helps show where Deborah K. Armstrong may publish in the future.
Co-authorship network of co-authors of Deborah K. Armstrong
This figure shows the co-authorship network connecting the top 25 collaborators of Deborah K. Armstrong. A scholar is included among the top collaborators of Deborah K. Armstrong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deborah K. Armstrong. Deborah K. Armstrong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Feng, Xinyi, et al.. (2025). The impact of cardiovascular risk factors on cancer progression: a prospective study in female breast cancer survivors. Breast Cancer Research and Treatment. 210(3). 737–748.
2.
Gaillard, Stéphanie, Christina Lacchetti, Deborah K. Armstrong, et al.. (2025). Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update. Obstetrical & Gynecological Survey. 80(7). 421–422.
3.
Visvanathan, Kala, Deborah K. Armstrong, Jin He, et al.. (2025). Cancer Susceptibility Gene Testing in Patients With Pancreatic Ductal Adenocarcinoma: Implementation in a Cancer Center Oncology Clinic. JCO Precision Oncology. 9(9). e2400494–e2400494.
4.
Salama, April K.S., Victoria Wang, Erin Macrae, et al.. (2024). Dabrafenib and trametinib in patients with tumors with BRAF V600E/k mutations: Updated results from NCI-MATCH arm H.. Journal of Clinical Oncology. 42(16_suppl). 3110–3110.
5.
Wethington, Stephanie L., Payal D. Shah, Lainie P. Martin, et al.. (2023). C ombination A TR (ceralasertib) and P A R P (olaparib) I nhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer. Clinical Cancer Research. 29(15). 2800–2807.
6.
Paller, Channing J., Lin Wang, Wei Fu, et al.. (2023). Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer. Cancer Research Communications. 3(2). 338–346.
7.
Walsh, Elaine M., John H. Fetting, Deborah K. Armstrong, et al.. (2021). Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes. Clinical Breast Cancer. 22(4). 319–325.
8.
Litvak, Anya M., Stuart D. Russell, Hua‐Ling Tsai, et al.. (2018). Racial disparities in the rate of cardiotoxicity of HER2‐targeted therapies among women with early breast cancer. Cancer. 124(9). 1904–1911.
9.
Hyman, David M., Naiyer A. Rizvi, Ronald B. Natale, et al.. (2018). Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. Clinical Cancer Research. 24(12). 2749–2757.
10.
Oliver, Kate, William E. Brady, Michael J. Birrer, et al.. (2017). An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Gynecologic Oncology. 147(2). 243–249.
11.
Wright, Alexi A., Kari Bohlke, Deborah K. Armstrong, et al.. (2016). Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Obstetrical & Gynecological Survey. 71(12). 717–718.
12.
Gross, Amy L., et al.. (2015). Weight Change in Breast Cancer Survivors Compared to Cancer-Free Women: A Prospective Study in Women at Familial Risk of Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. 24(8). 1262–1269.
13.
Tewari, Devansu, James Java, Ritu Salani, et al.. (2015). Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer. Obstetrical & Gynecological Survey. 70(8). 505–506.
14.
Tian, Chunqiao, Christine B. Ambrosone, Kathleen M. Darcy, et al.. (2011). Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: A Gynecologic Oncology Group study. Gynecologic Oncology. 124(3). 575–581.
15.
Krivak, Thomas C., Kathleen M. Darcy, Chunqiao Tian, et al.. (2008). Relationship Between ERCC1 Polymorphisms, Disease Progression, and Survival in the Gynecologic Oncology Group Phase III Trial of Intraperitoneal Versus Intravenous Cisplatin and Paclitaxel for Stage III Epithelial Ovarian Cancer. Journal of Clinical Oncology. 26(21). 3598–3606.
16.
Bristow, Robert E., Antonio Santillan, Teresa Díaz-Montes, et al.. (2007). Centralization of care for patients with advanced‐stage ovarian cancer. Cancer. 109(8). 1513–1522.
17.
Lehman, Constance D., Claudine Isaacs, Mitchell D. Schnall, et al.. (2007). Cancer Yield of Mammography, MR, and US in High-Risk Women: Prospective Multi-Institution Breast Cancer Screening Study. Radiology. 244(2). 381–388.
18.
Gottesman, Rebecca F., et al.. (2006). Optic neuropathy from metastatic squamous cell carcinoma of the cervix: An unusual CNS presentation. Gynecologic Oncology. 102(1). 121–123.
19.
Díaz-Montes, Teresa, Hongxiu Ji, Ann E. Smith Sehdev, et al.. (2005). Clinical significance of Her-2/neu overexpression in uterine serous carcinoma. Gynecologic Oncology. 100(1). 139–144.
20.
BenEzra, D., et al.. (1988). Prospective study of infections in indwelling central venous catheters using quantitative blood cultures1. The American Journal of Medicine. 85. 495–498.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Robert A. Burger Breakdown of academic impact, for papers by Gabriella Ferrandina Breakdown of academic impact, for papers by Pierluigi Benedetti Panici Breakdown of academic impact, for papers by William A. Cliby Breakdown of academic impact, for papers by Maurie Markman Breakdown of academic impact, for papers by Jonathan S. Berek Breakdown of academic impact, for papers by Thomas J. Herzog Breakdown of academic impact, for papers by Gordon Rustin Breakdown of academic impact, for papers by Jalid Sehouli Breakdown of academic impact, for papers by Ross S. Berkowitz